Market Overview

TherapeuticsMD Shares Rally +27% On FBR's Initiation

TherapeuticsMD Makes Innovation In Compliance Packaging For Its Prenatal Vitamins
Goldman Believes TherapeuticsMD Is 'Revitalizing Women's Health,' Initiates With Buy

Shares of TherapeuticsMD (NYSE: TXMD) gained 27.6 percent following FBR's initiation. FBR analyst William Tanner initiated coverage on TherapeuticsMD with an Outperform rating and $34.00 price target.

Tanner reported that TherapeuticsMD's TX-001 is likely the only FDA approved bio-identical hormone formulation. The analyst added that the formulation could even change the way women are treated with hormone replacement therapy. FBR emphasized that the company is truly a “big deal” in regards to women's health.

The analyst further noted that TherapeuticsMD may attract a large pharma partner.

Shares of TherapeuticsMD closed at $4.13 on Monday. The stock gained 27.6 percent to $5.27 before seeing some selloff. The stock is currently up 24.4 percent.

Latest Ratings for TXMD

Apr 2016Goldman SachsInitiates Coverage onBuy
Jun 2015GuggenheimInitiates Coverage onBuy
Jul 2014FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBRAnalyst Color Health Care Price Target Initiation Hot Analyst Ratings General


Related Articles (TXMD)

View Comments and Join the Discussion!